CervoMed (CRVO) Competitors

iTeos Therapeutics (NASDAQ:ITOS) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.

Does the MarketBeat Community believe in ITOS or CRVO?

iTeos Therapeutics received 23 more outperform votes than CervoMed when rated by MarketBeat users. However, 82.14% of users gave CervoMed an outperform vote while only 80.70% of users gave iTeos Therapeutics an outperform vote.

Company	Underperform	Outperform
iTeos Therapeutics	Outperform Votes 46 80.70%	Underperform Votes 11 19.30%
CervoMed	Outperform Votes 23 82.14%	Underperform Votes 5 17.86%

Do institutionals & insiders have more ownership in ITOS or CRVO?

97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of CervoMed shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 36.3% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more risk & volatility, ITOS or CRVO?

iTeos Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, CervoMed has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.

Is ITOS or CRVO more profitable?

iTeos Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -118.68%. iTeos Therapeutics' return on equity of -20.11% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	-20.11%	-17.50%
CervoMed	-118.68%	-44.11%	-39.81%

Which has stronger valuation and earnings, ITOS or CRVO?

CervoMed has lower revenue, but higher earnings than iTeos Therapeutics. CervoMed is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	$35M	6.29	-$112.64M	-$3.31	-1.74
CervoMed	$7.14M	12.63	-$2.17M	-$2.03	-5.11

Does the media favor ITOS or CRVO?

In the previous week, CervoMed had 9 more articles in the media than iTeos Therapeutics. MarketBeat recorded 12 mentions for CervoMed and 3 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 0.62 beat CervoMed's score of 0.27 indicating that iTeos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iTeos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CervoMed	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer ITOS or CRVO?

iTeos Therapeutics presently has a consensus price target of $25.75, indicating a potential upside of 346.66%. CervoMed has a consensus price target of $27.50, indicating a potential upside of 165.34%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe iTeos Therapeutics is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

iTeos Therapeutics beats CervoMed on 10 of the 19 factors compared between the two stocks.